» Articles » PMID: 15831938

Entry of the Vaccinia Virus Intracellular Mature Virion and Its Interactions with Glycosaminoglycans

Overview
Journal J Gen Virol
Specialty Microbiology
Date 2005 Apr 16
PMID 15831938
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

Vaccinia virus (VACV) produces two distinct enveloped virions, the intracellular mature virus (IMV) and the extracellular enveloped virus (EEV), but the entry mechanism of neither virion is understood. Here, the binding and entry of IMV particles have been investigated. The cell receptors for IMV are unknown, but it was proposed that IMV can bind to glycosaminoglycans (GAGs) on the cell surface and three IMV surface proteins have been implicated in this. In this study, the effect of soluble GAGs on IMV infectivity was reinvestigated and it was demonstrated that GAGs affected IMV infectivity partially in some cells, but not at all in others. Therefore, binding of IMV to GAGs is cell type-specific and not essential for IMV entry. By using electron microscopy, it is demonstrated that IMV from strains Western Reserve and modified virus Ankara enter cells by fusion with the plasma membrane. After an IMV particle bound to the cell, the IMV membrane fused with the plasma membrane and released the virus core into the cytoplasm. IMV surface antigen became incorporated into the plasma membrane and was not left outside the cell, as claimed in previous studies. Continuity between the IMV membrane and the plasma membrane was confirmed by tilt-series analysis to orientate membranes perpendicularly to the beam of the electron microscope. This analysis shows unequivocally that IMV is surrounded by a single lipid membrane and enters by fusion at the cell surface.

Citing Articles

MPXV: Update on Morphological and Morphogenesis Aspects Through Transmission and Scanning Electron Microscopies and 3D Reconstruction.

Barreto-Vieira D, Miranda M, da Silva M, de Almeida A, de Almeida A, Bandeira D J Med Virol. 2025; 97(1):e70180.

PMID: 39825732 PMC: 11742698. DOI: 10.1002/jmv.70180.


Trimerized S expressed by modified vaccinia virus Ankara (MVA) confers superior protection against lethal SARS-CoV-2 challenge in mice.

Zhu J, Wang Z, Li Y, Zhang Z, Ren S, Wang J J Virol. 2024; 98(7):e0052124.

PMID: 38874361 PMC: 11264693. DOI: 10.1128/jvi.00521-24.


The vaccinia chondroitin sulfate binding protein drives host membrane curvature to facilitate fusion.

Pokorny L, Burden J, Albrecht D, Bamford R, Leigh K, Sridhar P EMBO Rep. 2024; 25(3):1310-1325.

PMID: 38321165 PMC: 10933376. DOI: 10.1038/s44319-023-00040-2.


Structural and functional analysis of vaccinia viral fusion complex component protein A28 through NMR and molecular dynamic simulations.

Kao C, Tsai M, Carillo K, Tzou D, Chang W PLoS Pathog. 2023; 19(11):e1011500.

PMID: 37948471 PMC: 10664964. DOI: 10.1371/journal.ppat.1011500.


Emerging evidence on Monkeypox: resurgence, global burden, molecular insights, genomics and possible management.

Sharma R, Chen K, Sharma R Front Cell Infect Microbiol. 2023; 13:1134712.

PMID: 37153147 PMC: 10154632. DOI: 10.3389/fcimb.2023.1134712.